Ohsu Knight Cancer Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.ohsu.edu/knight-cancer-institute

Clinical Trials

MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma

Not Applicable

Recruiting

Conditions: Cutaneous Melanoma
Skin Carcinoma
Melanocytic Nevus

Interventions: Other: Confocal Microscopy
Other: Dermoscopy
Procedure: Imaging Technique
Drug: Lidocaine
Procedure: Punch Biopsy
Procedure: Shave Biopsy

First Posted Date: 2018-10-09

Last Posted Date: 2024-04-03

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 100

Registration Number: NCT03699995

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Video Distraction to Decrease Use of Sedation in Pediatric Participants During Radiation Therapy

Phase 1

Completed

Conditions: Malignant Neoplasm

Interventions: Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Radiation Therapy
Other: Video

First Posted Date: 2018-09-19

Last Posted Date: 2020-05-04

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 6

Registration Number: NCT03677531

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Feasibility of FMISO in Brain Tumors

Phase 2

Recruiting

Conditions: Malignant Brain Neoplasm

Interventions: Drug: ¹⁸F-Fluoromisonidazole
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Procedure: Oxygen Therapy

First Posted Date: 2018-08-28

Last Posted Date: 2024-03-13

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 50

Registration Number: NCT03649880

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Exercise Program Among Lung Cancer Dyads

Not Applicable

Completed

Conditions: Quality of Life
Pain
Physical Activity
Lung Cancer Symptoms
Lung Cancer
Depression

Interventions: Behavioral: Exercise Intervention
Other: Survey Administration
Other: Quality-of-Life Assessment

First Posted Date: 2018-08-28

Last Posted Date: 2020-12-09

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 46

Registration Number: NCT03649737

Locations: 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸
VA Portland Health Care System, Portland, Oregon, United States

EXERCISING TOGETHER for Couples Coping With Cancer

Not Applicable

Completed

Conditions: Stage I Prostate Cancer AJCC v8
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Malignant Solid Neoplasm
Colorectal Carcinoma
Breast Carcinoma
Stage I Colorectal Cancer AJCC v8
Stage II Colorectal Cancer AJCC v8
Stage III Prostate Cancer AJCC v8

Interventions: Behavioral: Exercise Intervention
Other: Questionnaire Administration
Other: Informational Intervention

First Posted Date: 2018-08-14

Last Posted Date: 2024-11-26

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 534

Registration Number: NCT03630354

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Bone Marrow Transplantation Using CD34-Selected Stem Cells From Related or Unrelated Donors in Treating Participants With Cancer or Other Disorders

Conditions: Hematopoietic Cell Transplantation Recipient
Malignant Neoplasm
Benign Neoplasm
Bone Marrow Transplantation Recipient

First Posted Date: 2018-08-13

Last Posted Date: 2024-08-16

Lead Sponsor: OHSU Knight Cancer Institute

Registration Number: NCT03626285

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma

Early Phase 1

Withdrawn

Conditions: Stage III Adult Soft Tissue Sarcoma
Stage II Adult Soft Tissue Sarcoma
Stage IIA Adult Soft Tissue Sarcoma
Stage IIB Adult Soft Tissue Sarcoma
Stage IIC Adult Soft Tissue Sarcoma
Stage IV Adult Soft Tissue Sarcoma

Interventions: Drug: Fluorothymidine F-18
Other: Laboratory Biomarker Analysis
Procedure: Positron Emission Tomography

First Posted Date: 2018-08-03

Last Posted Date: 2020-06-09

Lead Sponsor: OHSU Knight Cancer Institute

Registration Number: NCT03613259

JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2

Terminated

Conditions: Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions: Drug: Edicotinib
Other: Pharmacokinetic Study

First Posted Date: 2018-06-15

Last Posted Date: 2021-12-02

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 3

Registration Number: NCT03557970

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

Phase 1

Completed

Conditions: Anatomic Stage IV Breast Cancer AJCC v8
Estrogen Receptor Negative
HER2/Neu Negative
Prognostic Stage IV Breast Cancer AJCC v8
Triple-Negative Breast Carcinoma
Progesterone Receptor Negative

Interventions: Biological: Durvalumab
Drug: Olaparib

First Posted Date: 2018-06-01

Last Posted Date: 2020-11-20

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 3

Registration Number: NCT03544125

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Exercising Together During Radiation Treatment

Not Applicable

Completed

Conditions: Prostate Carcinoma
Spouse
Domestic Partnership

Interventions: Behavioral: Exercise Intervention
Other: Questionnaire Administration
Other: Survey Administration

First Posted Date: 2018-02-01

Last Posted Date: 2020-10-08

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 24

Registration Number: NCT03418025

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy